Melanoma and Kidney Cancer Group

Dr James Larkin and Dr Samra Turajlic's Group works to conceive and conduct clinical trials to increase understanding of the biology of these diseases and develop better treatments for them.

Research, projects and publications in this group

We are interested in how particular genetic changes and the order in which they happen impacts cancer progression, metastasis and treatment in both a clinical and translational setting. 

We conduct both clinical and translational research.

In the translational setting we study genetic changes in melanoma and kidney cancers and their interaction with the cancer environment, in particular the immune system.

We are interested in how particular genetic changes and the order in which they happen impacts cancer progression, metastasis and treatment. We are tracking these changes in the blood to find out if they reflect what is happening at the level of the tumour.

Ultimately we want to translate these observations into clinical applications that help us manage our patients.

The group is pursuing a number of projects:

  1. Understanding Renal Cancer Evolution
  2. Understanding Melanoma
  3. Tracking cancer evolution in the patient’s blood
  4. Understanding the mechanisms of immunotherapy toxicity

Professor James Larkin

Honorary Faculty:

Melanoma and Kidney Cancer Dr James Larkin

Professor James Larkin is a Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of melanoma and kidney cancer, and a Reader at the ICR.

See profile

Professor Samra Turajlic

Group Leader:

Melanoma and Kidney Cancer Dr Samra Turajlic (Profile Picture)

Professor Samra Turajlic is a Consultant Medical Oncologist at The Royal Marsden specialising in the treatment of kidney cancer and melanoma. She is a Cancer Research UK Clinician Scientist at the Francis Crick Institute and Associate Honorary Faculty at the Institute of Cancer Research.

See profile

Researchers in this group

Recent discoveries from this group